The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Graphite Bio Inc. (GRPH) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.02, or 1.08%, to $1.87. The Graphite Bio Inc. has recorded 7,537 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease.
Graphite Bio Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $1.85 and fluctuated between $1.9500 as its day high and $1.5900 as its day low. The current market capitalization of Graphite Bio Inc. is $177.90M. A total of 4.86 million shares were traded on the day, compared to an average of 253.15K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, GRPH has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 7 BUYs and 0 SELLs from insiders. Insiders purchased 650,134 shares during that period but sold 0.
In the most recent transaction, Samsara BioCapital, L.P. bought 350,000 shares of GRPH for 4.08 per share on Apr 12. After the transaction, the 10% Owner now owns 8,459,314 company shares. In a previous transaction on Apr 11, Samsara BioCapital, L.P. bought 74,464 shares at 4.07 per share. GRPH shares that 10% Owner owns now total 8,109,314.
Among the insiders who bought shares, Gutry Phil acquired of 5,000 shares on Apr 11 at a per-share price of $4.01. This resulted in the CHIEF BUSINESS OFFICER holding 299,941 shares of GRPH after the transaction. In another insider transaction, Samsara BioCapital, L.P. bought 23,000 shares at $8.70 per share on Jan 24. Company shares held by the 10% Owner now total 8,034,850.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for GRPH in the last 3 months, the mean price target is $7.43 with high estimates of $18.00 and low estimates of $2.00. In terms of 52-week highs and lows, GRPH has a high of $11.54 and a low of $2.07.
As of this writing, GRPH has an earnings estimate of -$0.46 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.29 per share and a lower estimate of -$0.52. The company reported an EPS of -$0.48 in the last quarter, which was -23.10% lower than expectations of -$0.39.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GRPH is Overweight with a score of 4.25. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 4 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.